Epigenetics

Epigenetics research delves into the molecular mechanisms that control gene expression and cellular traits without altering the underlying DNA sequence. One crucial aspect of this field is the role of small molecules, which act as powerful regulators of epigenetic modifications. These small compounds, typically comprising a few dozen to a few hundred atoms, have emerged as essential tools in understanding and manipulating the epigenome.

  • DNA Methylation Inhibitors: Small molecules like 5-azacytidine and 5-aza-2'-deoxycytidine are DNA methyltransferase inhibitors. They block the addition of methyl groups to DNA, leading to DNA demethylation. This can reactivate silenced genes, potentially offering therapeutic avenues for conditions like cancer.
  • HDAC inhibitors: HDACs remove acetyl groups from histone proteins, contributing to gene repression. Small molecule HDAC inhibitors, such as Vorinostat and Romidepsin, can reverse this process by increasing histone acetylation, allowing genes to be more accessible for transcription. These inhibitors are being explored for cancer therapy and other conditions.
  • Histone Methyltransferase Inhibitors: Small molecules like GSK126 inhibit specific histone methyltransferases, affecting histone methylation patterns. This can alter gene expression, making them promising candidates for cancer and other diseases with epigenetic dysregulation.
  • RNA Modulators: Small molecules can also target non-coding RNAs involved in epigenetic regulation. For instance, small molecules called small interfering RNAs (siRNAs) can be designed to target and degrade specific long non-coding RNAs, influencing gene expression.
  • Epigenetic Reader Domain Inhibitors: These small molecules target proteins that recognize and bind to specific epigenetic marks. Examples include inhibitors of bromodomain-containing proteins (BET inhibitors), which can disrupt gene regulation by interfering with protein-DNA interactions.

Small molecules in epigenetics research not only provide insights into the fundamental biology of gene regulation but also hold immense promise for developing novel therapeutics. Their ability to selectively modulate specific epigenetic marks and pathways has led to ongoing clinical trials and drug development efforts for various diseases, including cancer, neurological disorders, and inflammatory conditions. Understanding and harnessing the power of these small molecules is at the forefront of modern epigenetics research, offering new hope for precision medicine and targeted therapies.


3 key components involved in the regulation of epigenetic modifications

Epigenetics Writer

Epigenetics writers are enzymes responsible for adding chemical marks or modifications to DNA or histone proteins. These marks include DNA methylation (addition of methyl groups to DNA) and histone modifications (such as acetylation, methylation, phosphorylation, etc.).

Epigenetics Reader

Function: Epigenetics readers are proteins that can recognize and bind to specific epigenetic marks on DNA or histones. These reader proteins interpret the epigenetic code and facilitate downstream cellular processes, such as gene activation or repression.

Epigenetics Eraser

Function: Epigenetics erasers are enzymes responsible for removing or reversing epigenetic marks on DNA or histones. This process allows for the dynamic regulation of gene expression and the resetting of epigenetic states during various stages of development and in response to environmental changes.

Shop By

Items 1951-2000 of 2164

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. BET Inhibitor

    EBET-590 is a potent bromodomain and extraterminal (BET) inhibitor that selectively targets BET proteins, disrupting their interactions with acetylated histones. This compound exhibits significant anti-proliferative activity in various cancer cell lines, making it a valuable tool for cancer research. It is particularly relevant for studies focused on epigenetic regulation and the development of targeted cancer therapies.
  2. BET Inhibitor

    BET-IN-7 is a potent inhibitor of bromodomain and extra-terminal (BET) proteins, exhibiting a Ki value of 12.27 μM and a Kd of 89.3 μM. This compound demonstrates significant potential in research related to sepsis and other inflammatory conditions by modulating transcriptional regulation. Its ability to interfere with BET protein activity makes it a valuable tool for studying epigenetic processes and developing therapeutic strategies against related diseases.
  3. BET Inhibitor

    BET-IN-21 is a selective BET inhibitor targeting the extra terminal domain, demonstrating a Ki of 230 nM. This compound effectively inhibits microglial activation and exhibits therapeutic benefits in models of experimental autoimmune encephalomyelitis. It serves as a valuable tool for research into neuroinflammation and related neurodegenerative disorders.
  4. BET Bromodomain Inhibitor

    BET-IN-18 is a pan-BET bromodomain inhibitor targeting Brd4 and BrdT. It exhibits potent competitive inhibition of the binding of acetylated histone substrates as well as the known BET inhibitor (+)-JQ1, with IC50 values of 1.0 μM and 2.3 μM for Brd4 and BrdT, respectively. This compound is useful for investigating BET bromodomain functions in various biological contexts, particularly in the study of multiple myeloma.
  5. BRD 4/p38α/BRDT Inhibitor

    SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways.
  6. BRD4 BD1 Inhibitor

    3-Methylcarbostyril is a selective inhibitor of the bromodomain protein BRD4 BD1, exhibiting a pIC50 value of 4.4. This compound has been utilized in research to investigate the role of BRD4 in various cellular processes, including transcription regulation and oncogenic signaling. Its inhibitory activity makes it a valuable tool for studies focused on cancer therapy and epigenetic modulation.
  7. BRD4 BD1 Inhibitor

    ZL0516 is a selective inhibitor of the BRD4 bromodomain 1 (BD1), demonstrating potent activity in modulating epigenetic regulation. It effectively suppresses inflammatory bowel disease (IBD) through inhibition of the BRD4/NF-κB signaling pathway, which plays a critical role in inflammation and immune responses. This compound is primarily utilized in research focusing on the development of therapeutic strategies for IBD and related inflammatory conditions.
  8. BRDT-BD2 Inhibitor

    CDD-1132 is a potent BRDT-BD2 inhibitor with an IC50 of 13 nM, demonstrating significant selectivity for this target. It plays a crucial role in research applications focused on nonhormonal contraceptive agents by interfering with the bromodomain's function. This compound offers potential insights into the development of innovative reproductive health solutions.
  9. BET Inhibitor

    BET-IN-29 is a bromodomain and extraterminal motif (BET) inhibitor that modulates protein-protein interactions involved in gene regulation. It exhibits potent anti-cancer activity by disrupting the function of BET proteins, which play a critical role in cellular proliferation and survival. This compound is applicable in various research areas, including cancer biology, inflammation, metabolic disorders, neurological diseases, and infectious diseases, making it a valuable tool for elucidating underlying mechanisms in these fields.
  10. BRD4-BD1/2 Inhibitor

    BRD4-BD1/2-IN-1 is a potent inhibitor targeting the bromodomain receptor BRD4, exhibiting IC50 values of less than 100 nM for both BRD4 BD-1 and BD-2. This compound plays a crucial role in modulating gene expression through its interactions with chromatin. It is commonly utilized in research applications focused on cancer biology and therapeutic strategies targeting epigenetic regulation.
  11. BET Inhibitor

    BET-IN-15 is a potent bromodomain and extraterminal (BET) inhibitor that targets BRD4 with IC50 values of 0.64 nM and 0.25 nM for BRD4-BD1 and BRD4-BD2, respectively. This compound exhibits significant antiproliferative activity, making it an important tool for studying the role of BET proteins in cancer and other diseases. Researchers can utilize BET-IN-15 in investigations of transcriptional regulation and the therapeutic potential of BET inhibition in oncology.
  12. BRD4 Inhibitor

    BRD4 Inhibitor-17 is a potent BRD4 inhibitor with an IC50 of 0.33 μM. This compound is involved in the regulation of transcription associated with inflammatory responses, cellular proliferation, and cell cycle progression. BRD4 Inhibitor-17 holds potential as a therapeutic agent for counteracting the effects of arsenical compounds in research applications.
  13. BET Inhibitor

    BET-IN-12 is an orally active inhibitor of bromodomain and extra-terminal (BET) proteins, specifically targeting BRD4 with an IC50 of 0.9 nM. This compound demonstrates significant ability to disrupt BET protein interactions with acetylated lysines, thereby influencing gene expression and cellular signaling pathways. BET-IN-12 is utilized in research exploring therapeutic strategies for various cancers and inflammatory diseases, making it a valuable tool for studying the role of BET proteins in these conditions.
  14. BET Inhibitor

    BET-IN-8 is a potent bromodomain and extraterminal (BET) inhibitor, with a Ki value of 0.83 μM and a Kd of 0.571 μM. This compound exhibits significant biological activity by ameliorating lipopolysaccharide (LPS)-induced sepsis in vivo. BET-IN-8 is valuable for research applications focused on understanding the role of BET proteins in inflammatory responses and sepsis pathophysiology.
  15. SMARCA2 Inhibitor

    SMARCA2-IN-1 is a selective inhibitor of the SWI/SNF chromatin remodeling complex, specifically targeting SMARCA2. With an IC50 of greater than 1000 nM in H1299 cell lines, this compound is useful for studying the role of SMARCA2 in chromatin dynamics and epigenetic regulation. It has potential applications in cancer research, particularly in understanding the implications of chromatin remodeling in tumor progression and therapeutic resistance.
  16. BRD4 Inhibitor

    BRD4-IN-8 is a selective inhibitor of the bromodomain-containing protein 4 (BRD4). It modulates gene expression by disrupting the interaction between BRD4 and acetylated histones, leading to the inhibition of transcriptional elongation. This compound has been shown to exhibit anti-cancer activity and is utilized in research investigating the therapeutic potential of targeting the BRD4 pathway in various malignancies.
  17. BET Inhibitor

    Repibresib is a selective Bromodomain and Extra-Terminal (BET) inhibitor that targets BET proteins involved in the regulation of gene expression. This compound exhibits significant antineoplastic activity, making it a valuable tool for cancer research. Its ability to disrupt the interaction between BET proteins and acetylated lysines can be utilized in the study of various malignancies and in the development of novel therapeutic strategies.
  18. BRD4 Inhibitor

    BRD4-IN-4 is a selective inhibitor of the bromodomain-containing protein 4 (BRD4) with an IC50 of 6.83 μM. This compound effectively inhibits the proliferation of MV4-11 cells and induces cell cycle arrest in the G1 phase. BRD4-IN-4 is primarily utilized in research focused on MLL leukemia, providing insights into the therapeutic potential of targeting BRD4 in cancer treatment.
  19. BET Inhibitor

    GSK-340 is a potent BET inhibitor that exhibits high affinity and selectivity for the bromodomain BD2 of BRD4, with a pIC50 value of 7.2. This compound effectively inhibits the release of MCP-1 in lipopolysaccharide-treated PBMCs and whole blood, demonstrating pIC50 values of 7.4 and 6.0, respectively. GSK-340's immunomodulatory properties make it a valuable tool for research applications in inflammation and cancer biology.
  20. Pan-BRD4-D1-Biased/BRD4-D2 Inhibitor

    DW34 is a pan-BRD4-D1 biased inhibitor with concurrent inhibitory activity against BRD4-D2. It demonstrates potent biological activity with an EC50 of 0.14 μM, making it effective in modulating BRD4 pathways. DW34 significantly mitigates liver inflammation induced by lipopolysaccharide (LPS) and acetaminophen (APAP), primarily by reducing chemokine expression and cellular necrosis. This compound is suitable for research applications focused on inflammatory diseases and BRD4-related pathways.
  21. BRD4 Inhibitor

    CN427 is a quinazoline-based compound that selectively inhibits the bromodomain-containing protein 4 (BRD4) with a Kd of 66 nM. This inhibition disrupts the interaction between BRD4 and acetylated histones, which can lead to altered transcriptional regulation. CN427 is primarily applicable in leukemia research, providing insights into epigenetic modulation and potential therapeutic strategies in this malignancy.
  22. BRD4 BD2 Inhibitor

    BRD4-BD1/2-IN-2 is a highly selective inhibitor targeting the BD2 domain of BRD4, demonstrating IC50 values of less than 0.5 nM for BRD4 BD2 and approximately 300 nM for BRD4 BD1. This compound exhibits significant biological activity in modulating BRD4-related pathways, making it a valuable tool for research in oncology and epigenetic regulation. Its potency and specificity support further exploration of BRD4 as a therapeutic target in various diseases.
  23. BET Inhibitor

    BET-IN-10 is a potent BET inhibitor that selectively targets bromodomain and extraterminal (BET) proteins, crucial for regulating gene expression. This compound demonstrates significant anticancer activity, notably inhibiting the growth of MV4-11 leukemia cells with an IC50 value of 26.5 nM. BET-IN-10 is valuable for research applications focused on cancer biology and the mechanistic study of BET-mediated signaling pathways.
  24. BRD4 Inhibitor

    BRD4 Inhibitor-28 is a selective inhibitor of the bromodomain protein BRD4, targeting the BRD4-BD1 and BRD4-BD2 domains with IC50 values of 15 nM and 55 nM, respectively. Additionally, it demonstrates inhibitory effects on BRD2-BD1, BRD3-BD1, and BRDT-BD1, with IC50 values of 19 nM, 25 nM, and 68 nM. This compound exhibits notable anti-melanoma activity, making it valuable for research in cancer therapeutics and epigenetic modulation.
  25. BET Inhibitor

    SJ1461 is a potent BET inhibitor that selectively targets bromodomain-containing proteins BRD2 and BRD4. It demonstrates high affinity with IC50 values of 1.6 nM for BRD2 (BD1), 0.1 nM for BRD2 (BD2), 6.5 nM for BRD4 (BD1), and 0.2 nM for BRD4 (BD2). SJ1461 is utilized in research applications related to cancer, inflammation, and epigenetic regulation, making it a valuable tool for investigating the role of BET proteins in various biological processes.
  26. BRD4 Inhibitor

    Y02224 is a potent inhibitor of the bromodomain-containing protein 4 (BRD4), which plays a critical role in regulating gene expression and cellular proliferation. This compound exhibits significant antiproliferative activity against leukemia cells, highlighting its potential in cancer research. Additionally, Y02224 may be valuable in investigating therapeutic strategies for castration-resistant prostate cancer (CRPC).
  27. BRD4 D1 Inhibitor

    BRD4 D1-IN-2 is a selective inhibitor targeting BRD4 D1, exhibiting a potent IC50 of less than 0.092 µM. With an affinity of 15 nM for BRD4 D1, this compound demonstrates over 500-fold selectivity against both BRD2 D1 and BRD4 D2, as determined by isothermal titration calorimetry (ITC). BRD4 D1-IN-2 is valuable for research applications exploring the role of BRD4 in epigenetic regulation and its implications in cancer and other diseases.
  28. BRD4 Inhibitor

    BRD4-IN-5 is a selective inhibitor of the bromodomain protein BRD4. It demonstrates notable activity with Ki values of 9.7 nM for the first bromodomain (BDI) and 16.1 nM for the second bromodomain (BDII). This compound is valuable for use in cancer research, particularly in studies exploring the role of BRD4 in oncogenic transcriptional regulation and therapeutic interventions.
  29. BRDT-BD2 Inhibitor

    CDD-1154 is an aminopyrimidine analog that functions as a specific inhibitor of the bromodomain testis-specific protein BRDT-BD2, with an IC50 of 139 nM. This compound is primarily utilized in male contraceptive research, providing valuable insights into fertility regulation and the development of novel contraceptive methods. Its selective activity against BRDT-BD2 supports investigations into potential therapeutic applications in reproductive health.
  30. BRD4 Inhibitor

    BRD4 Inhibitor-29 is a selective bromodomain-containing protein 4 (BRD4) inhibitor with an IC50 of less than 100 nM. This compound exhibits notable antiproliferative effects against prostate cancer cells, making it a valuable tool for investigating the role of BRD4 in cancer biology and therapeutic applications. It can be utilized in research aimed at understanding the mechanisms of tumorigenesis and developing new treatment strategies for BRD4-dependent cancers.
  31. CBP Inhibitor

    DC-CPin7 is a selective inhibitor of the CREB-binding protein (CBP) bromodomain, demonstrating an IC50 value of 2.5 μM. This compound modulates CBP-mediated signaling pathways, making it relevant for studies involving transcriptional regulation and epigenetic modifications. DC-CPin7 is suitable for research applications focused on cancer biology and other diseases linked to dysregulated gene expression.
  32. BET Inhibitor

    XL-126 is a selective inhibitor of the bromodomain and extraterminal (BET) protein family, specifically targeting BD1 with a Kd of 8.9 nM. This compound demonstrates significant anti-inflammatory properties while preserving platelet function, making it a valuable tool for research into inflammatory disorders and hematological conditions. XL-126 is particularly useful in studies aimed at understanding the role of BET proteins in disease pathways and therapeutics.
  33. BRD4 Inhibitor

    Penipanoid C is a selective BRD4 inhibitor derived from the marine sediment-derived fungus Penicillium paneum SD-44. This compound exhibits anti-inflammatory properties and demonstrates cytotoxic effects on SMMC-7721 cells. Penipanoid C serves as a valuable tool for research into inflammatory diseases and related therapeutic applications.
  34. BRD4-BD1 Inhibitor

    BRD4-BD1-IN-2 is a selective inhibitor of BRD4-BD1, exhibiting an IC50 of 2.51 µM, demonstrating a 20-fold selectivity over BD2. This compound is valuable in research focused on cancer and cardiovascular diseases, facilitating the investigation of BRD4’s role in oncogenic processes and cardiac function. Its specificity makes it a useful tool for probing the biological mechanisms underlying these conditions.
  35. BET Inhibitor

    XY153 is a BD2-selective BET inhibitor that primarily targets the bromodomain 2 (BD2) of the BRD4 protein. It exhibits potent binding affinity to BRD4 BD2, BRD3 BD2, and BRD2 BD2, with IC50 values of 0.79 nM, 5.31 nM, and 5.09 nM, respectively. XY153 demonstrates significant antiproliferative effects across various tumor cell lines and is applicable in research focused on acute myeloid leukemia (AML) and cancer therapeutics.
  36. SMARCA2-BRD Inhibitor

    DCSM06-05 is a potent inhibitor of the SMARCA2-BRD interaction, exhibiting an IC50 value of 9 µM and a Kd value of 22.4 µM. This compound is instrumental in studies focused on chromatin remodeling and precision oncology, as it modulates the activity of the SWI/SNF complex. Research applications include investigating the role of SMARCA2 in tumorigenesis and therapeutic resistance in various cancers.
  37. BET Bromodomain Inhibitor

    BET bromodomain inhibitor 3 selectively inhibits BET bromodomains, demonstrating an inhibitory effect against BrdT with a Ki value greater than 40 µM. This compound is instrumental in studying various biological processes and has potential applications in research related to contraception, cancer, and cardiovascular diseases. Its mechanism of action makes it a valuable tool for investigating the role of BET proteins in gene regulation and associated pathologies.
  38. SMARCA2 ATPase Inhibitor

    SMARCA2-IN-10 is a selective inhibitor of the SMARCA2 ATPase domain, with an IC50 value of 17.676 μM. This compound has been shown to induce cell death in tumors lacking SMARCA4, making it a valuable tool for investigating SMARCA4-mutant non-small cell lung cancer, small cell ovarian carcinoma, and melanoma. Its targeting of the SMARCA2 ATPase offers significant potential for advancing research in these cancer types.
  39. SMARCA2/4 Inhibitor

    SMARCA2/4-IN-1 is a selective inhibitor targeting SMARCA2 and SMARCA4, with reported IC50 values of 3.8 µM and 1.7 µM, respectively. This compound demonstrates significant inhibition of these chromatin remodeling factors, making it a valuable tool for studying epigenetic regulation and its impact on gene expression. It has potential applications in cancer research and therapeutic investigations aimed at manipulating chromatin dynamics.
  40. PBRM1 Bromodomain Inhibitor

    PBRM1-BD2-IN-4 is a selective inhibitor of the PBRM1 bromodomain, exhibiting Kd values of 5.5 μM and 11.1 μM for PBRM1-BD2 and PBRM1-BD5, respectively, with an IC50 of 0.2 μM for PBRM1-BD2. This compound is instrumental in studying the role of PBRM1 in cancer biology and may contribute to the development of anticancer therapies targeting bromodomain-containing proteins. Its high potency and specificity make it a valuable tool for research focused on epigenetic regulation in cancer contexts.
  41. BRD4 Inhibitor

    BRD4 Inhibitor-34 is a selective inhibitor of the bromodomain and extraterminal (BET) protein BRD4, exhibiting an IC50 value of 24 μM. This compound effectively disrupts BRD4's interaction with acetylated lysines, leading to the modulation of gene expression and cellular signaling pathways. BRD4 Inhibitor-34 is utilized in research applications involving cancer biology, inflammation, and epigenetic regulation, providing valuable insights into the therapeutic potential against various diseases.
  42. SMARCA Inhibitor

    SMARCA2-IN-4 is a selective inhibitor of the SWI/SNF chromatin remodeling complex, specifically targeting the bromodomains of SMARCA proteins. This compound demonstrates high binding affinity for PB1, SMARCA2B, and SMARCA4, with dissociation constants (Kd) of 124 nM, 262 nM, and 417 nM, respectively. SMARCA2-IN-4 is valuable for studies investigating the roles of chromatin remodeling in gene expression and cellular processes, offering potential insights into cancer biology and epigenetic regulation.
  43. BET Inhibitor

    BET-IN-1 is a potent inhibitor of bromodomain and extraterminal (BET) proteins, which play a crucial role in regulating gene expression through acetylated lysine recognition. It demonstrates significant brain penetration and favorable metabolic stability, making it a valuable tool for studying the role of BET proteins in various cellular processes. BET-IN-1 is particularly applicable in research related to cancer biology and neurodegenerative disorders, aiding in the exploration of therapeutic strategies targeting epigenetic regulation.
  44. BRD4 Inhibitor

    CeMMEC2 is a potent inhibitor of the bromodomain-containing protein 4 (BRD4) with an IC50 of 0.9 μM. This compound effectively disrupts BRD4-driven transcriptional programs, making it a valuable tool for studying epigenetic regulation. CeMMEC2 is particularly useful in cancer research and the investigation of inflammatory diseases, providing insights into therapeutic strategies targeting BRD4-mediated pathways.
  45. BRD4 Inhibitor

    BRD4-IN-6 is a selective inhibitor of the Bromodomain-containing protein 4 (BRD4), a critical regulator of gene expression and a key target in cancer research. This compound effectively disrupts the BRD4-dependent transcriptional activation, leading to decreased cell proliferation in various cancer models. Its application extends to studying the mechanisms of BRD4 in epigenetic regulation and the development of potential therapeutic strategies for cancer treatment.
  46. CBP Bromodomain Inhibitor

    Y08284 is a potent and selective inhibitor of the CBP bromodomain, exhibiting an IC50 of 4.21 nM. This compound effectively suppresses the proliferation of prostate cancer cell lines, including LNCaP, C4-2B, and 22Rv1. Its significant antitumor activity makes Y08284 a valuable tool for research focused on prostate cancer biology and bromodomain-related processes.
  47. CBP Bromodomain Inhibitor

    Y08175 is a highly potent inhibitor of the CBP bromodomain, demonstrating significant inhibitory capacity with IC50 values of 37 nM and 178.15 nM in AlphaScreen and HTRF assays, respectively. This compound is valuable for investigating the role of CBP in oncogenic processes, particularly in the context of prostate cancer research. Its ability to selectively target the CBP bromodomain makes it a useful tool for studying bromodomain-mediated transcriptional regulation and associated pathways.
  48. BET Bromodomain Inhibitor

    BET Bromodomain Inhibitor 2 selectively targets the bromodomains of BET proteins, exhibiting a potent inhibitory effect with an IC50 of 14.1 µM. This compound is critical for modulating gene expression linked to cancer and inflammation by disrupting the interaction between acetylated histones and BET proteins. It is applicable in various research contexts, including oncology and epigenetics studies, providing invaluable insights into therapeutic strategies targeting bromodomain-containing proteins.
  49. BRD4 Inhibitor

    BRD4-IN-9 is a potent inhibitor of BRD4, exhibiting an IC50 value of 9.4 nM. It demonstrates significant efficacy in suppressing tumor growth, specifically in a mouse melanoma xenograft model. This compound is valuable for research focusing on cancer biology and epigenetic regulation.
  50. Bromodomain Inhibitor

    Bromodomain inhibitor-10 is a selective bromodomain inhibitor that targets BRD4-1 and BRD4-2 with Kd values of 15.0 nM and 2500 nM, respectively. This compound effectively inhibits the production of IL-12p40, making it valuable in studies related to immune response and inflammation. It is suitable for research applications investigating the roles of bromodomain proteins in various biological processes and disease states.

Items 1951-2000 of 2164

Page
per page
Set Descending Direction